Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name AB-2100
Synonyms
Therapy Description

AB-2100 is an autologous integrated circuit T (ICT) cell therapy comprising T-cells engineered to express a PSMA-specific priming receptor, an inducible chimeric antigen receptor (CAR) that targets CA9, shRNA-microRNA that targets FAS and TGFBR2, and a synthetic pathway activator that activates STAT3 signaling, which potentially increases anti-tumor immune activity and induces cytotoxicity against tumor cells expressing both PSMA and CA9 (Journal for ImmunoTherapy of Cancer 2023;11).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AB-2100 AB 2100|AB2100 AB-2100 is an autologous integrated circuit T (ICT) cell therapy comprising T-cells engineered to express a PSMA-specific priming receptor, an inducible chimeric antigen receptor (CAR) that targets CA9, shRNA-microRNA that targets FAS and TGFBR2, and a synthetic pathway activator that activates STAT3 signaling, which potentially increases anti-tumor immune activity and induces cytotoxicity against tumor cells expressing both PSMA and CA9 (Journal for ImmunoTherapy of Cancer 2023;11).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06245915 Phase Ib/II AB-2100 AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) Active, not recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST